Bristol Myers Squibb Co (BMY)

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review...

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per...

Form 4 - Statement of changes in beneficial ownership of securities

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and...

Form 4 - Statement of changes in beneficial ownership of securities

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026 SystImmune and Bristol Myers...

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this...

Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III...

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

First Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO® 2026 SUCCESSOR-2 data reinforce the potential of CELMoD...

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference...

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein...

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

The collaboration brings together BMS’ deep scientific expertise and Anthropic's frontier AI to accelerate the discovery, development and...